Cargando…
Treating rheumatic patients with a malignancy
Management of patients with inflammatory rheumatic disease and a history of (or even a current) malignant disease poses some particular challenges. As direct evidence of the risk of (recurrent or de novo) malignancy in patients with a history of malignant disease is scarce, such a risk may be estima...
Autores principales: | Elandt, Katarzyna, Aletaha, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218895/ https://www.ncbi.nlm.nih.gov/pubmed/21722342 http://dx.doi.org/10.1186/ar3352 |
Ejemplares similares
-
Considering comorbidity in managing rheumatic diseases: going where trials cannot go
por: Aletaha, Daniel, et al.
Publicado: (2011) -
Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors
por: Melissaropoulos, Konstantinos, et al.
Publicado: (2020) -
Advances of autoimmune rheumatic diseases related to malignant tumors
por: Zhao, Miaomiao, et al.
Publicado: (2023) -
Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs)
por: De Cock, Diederik, et al.
Publicado: (2022) -
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
por: Lee, Kyung-Ann, et al.
Publicado: (2019)